Causes of under-reporting in Pharmacovigilance in Cameroon - Ngono Mballa, Rose;Nkuete, Géraldine;Wouessidjewe, Denis
17,99 €
inkl. MwSt.

Versandfertig in 1-2 Wochen
payback
9 °P sammeln
  • Broschiertes Buch

The objective of this study was to identify the causes of under-reporting of adverse drug events in hospitals in Cameroon. From a strategic point of view, we focused our work on three points: firstly, the evaluation of the knowledge of health professionals in pharmacovigilance; this study revealed an insufficient level of knowledge in pharmacovigilance among the categories of health professionals. Then the determination of their attitudes towards the manifestations of adverse drug events; it emerged that health professionals had a positive attitude towards ADRs in hospitals, that the…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
The objective of this study was to identify the causes of under-reporting of adverse drug events in hospitals in Cameroon. From a strategic point of view, we focused our work on three points: firstly, the evaluation of the knowledge of health professionals in pharmacovigilance; this study revealed an insufficient level of knowledge in pharmacovigilance among the categories of health professionals. Then the determination of their attitudes towards the manifestations of adverse drug events; it emerged that health professionals had a positive attitude towards ADRs in hospitals, that the proportion of adverse events varied according to the type of hospital and that the level of notification was the same in all reference levels. Finally, the factors that hinder the functioning of pharmacovigilance in hospitals were identified.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Rose Ngono Mballa war im Ministerium für öffentliche Gesundheit von Kamerun unter anderem: Direktorin für Pharmazie und Arzneimittel (1995-1998), temporäre Beraterin WHO/AFRO (1999-2001), technische Beamtin im Länderbüro der WHO Kamerun (2002-2011), Inspektorin für öffentliche Gesundheit (2013-2015) und seit Ende 2015 Generaldirektorin des LANACOME.